COMMUNIQUÉS West-GlobeNewswire

Curium prévoit d’augmenter considérablement sa capacité de production de lutécium-177 et son empreinte PET grâce à l’acquisition d’Eczacibaşi-Monrol
09/04/2024
Le projet d’acquisition d’Eczacıbaşı-Monrol va : Tirer parti de l’actuel partenariat dans le domaine du Lu-177 pour donner naissance à un fabricant de premier plan de cet isotope Ajouter 12 sites PET au réseau existant [...]
CLS Americas Announces 2nd Order of TRANBERG™ Focal Laser Ablation Accessories Placed by the National Institutes of Health Clinical Center
09/04/2024
CLS’s Single-Use, Sterile Instruments to be used in Research Study - MRI/Ultrasound Fusion-Guided FLA of Prostate Tissue and Prostate Cancer LOS ANGELES, April 09, 2024 (GLOBE NEWSWIRE) -- Clinical Laserthermia Systems [...]
Essential Pharma acquires Renaissance Pharma Ltd with its clinical stage immunotherapy for the treatment of high-risk neuroblastoma
09/04/2024
Essential Pharma acquires Renaissance Pharma Ltd with its clinical stage immunotherapy for the treatment of high-risk neuroblastoma First development-stage asset to be added to the Essential Pharma portfolio and second [...]
EssilorLuxottica closes the acquisition of Washin to grow its optical retail presence in Japan
09/04/2024
EssilorLuxottica closes the acquisition of Washin to grow its optical retail presence in Japan Complementing its investment in ‘made in Japan’ manufacturing, the transaction confirms the Group’s commitment to further [...]
EssilorLuxottica finalise l'acquisition de Washin et renforce sa présence dans la distribution optique au Japon
09/04/2024
EssilorLuxottica finalise l'acquisition de Washin et renforce sa présence dans la distribution optique au Japon Cette opération complète les investissements du Groupe dans la fabrication « Made in Japan » et confirme [...]
Basilea awarded CARB-X grant to develop recently acquired novel class of antibiotics
09/04/2024
Allschwil, Switzerland, April 09, 2024 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal [...]
Stifel Initiates Research Coverage of ONWARD® Medical with a Buy Rating and Target Price of EUR 12.00
09/04/2024
EINDHOVEN, the Netherlands, April 09, 2024 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative therapies to restore movement, function, and independence in people [...]
OKYO Pharma to Reschedule Key Opinion Leader Event in Dry Eye Disease to May 2024
09/04/2024
LONDON and NEW YORK, April 08, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflammatory dry eye [...]
Opthea Appoints John Han, PharmD, as VP Medical Affairs
09/04/2024
Brings extensive experience in retinal and ophthalmology diseases MELBOURNE, Australia and PRINCETON, N.J., April 08, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT “Opthea”, the “Company”), a clinical-stage [...]
Smith+Nephew signs exclusive distribution agreement to provide unique NAVBIT SPRINT™ solution in Australia
09/04/2024
Compact, single-use, and simple-to-use technology offers surgeons a fast, reliable navigation solution for hip arthroplasty Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, announced an agreement [...]
Premier Health Announces the Appointment of Bruno Morel as its New CTO
08/04/2024
MONTRÉAL, April 08, 2024 (GLOBE NEWSWIRE) -- Premier Health of America Inc. (TSXV: PHA) (the “ Corporation ” or “ Premier Health ”), a leading Canadian Health tech company, announces the appointment of Bruno Morel as [...]
Windtree Acquires Early-Stage, Novel Oncology Platform and Completes $1.5 Million Convertible Note Bridge Financing
08/04/2024
WARRINGTON, Pa., April 08, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), today announced that on April 2, 2024 the Company entered into an asset purchase agreement [...]
Onco360 Has Been Selected as the Sole National Specialty Pharmacy Partner for Voydeya® (danicopan)
08/04/2024
LOUISVILLE, Ky., April 08, 2024 (GLOBE NEWSWIRE) -- Onco360 ® , the nation’s leading independent Specialty Pharmacy, has been selected as a national pharmacy partner by Alexion Pharmaceuticals for Voydeya ® (Danicopan) [...]
Vincerx Pharma Presents Positive Preliminary Phase 1 Data for VIP236 and Updates on Pipeline Progress at the American Association for Cancer Research (AACR) Annual Meeting 2024
08/04/2024
VIP236 demonstrated positive signs of clinical activity, including tumor reduction, and an improved safety profile in heavily pretreated patients with metastatic solid tumors VIP943 pharmacokinetic (PK) data shows very [...]
Cellectis présentera deux posters sur un nouveau procédé d’édition par TALEN® pour la correction et l’insertion de gènes dans les cellules souches et progénitrices hématopoïétiques (HSPCs) à l’ASGCT
08/04/2024
NEW YORK, 08 avr. 2024 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), société de biotechnologie de stade clinique, qui utilise sa technologie pionnière d'édition de génome TALEN ® pour développer [...]
Cellectis Announces Two Poster Presentations on Novel TALEN® Editing Process for Gene Correction and Gene Insertion in HSPCs at the ASGCT Annual Meeting
08/04/2024
NEW YORK, April 08, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving [...]
Olema Oncology to Participate in Canaccord Genuity 2024 Horizons in Oncology Virtual Conference
08/04/2024
SAN FRANCISCO, April 08, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema”, “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and [...]
Theratechnologies Preclinical Data Presentation at AACR 2024 Highlights Versatility and Flexibility of SORT1+ Technology™ Oncology Platform
08/04/2024
Novel camptothecin-peptide conjugates are well tolerated and associated with significant tumor regression in colorectal cancer and triple-negative breast cancer xenograft models SORT1 gene silencing results in drastic [...]
Theratechnologies présente des données précliniques au congrès 2024 de l’AACR qui met en évidence la polyvalence et la flexibilité de la plateforme technologique d’oncologie SORT1+(MC)
08/04/2024
Les nouveaux conjugués camptothécine-peptide sont bien tolérés et associés à une régression tumorale marquée dans les modèles de xénogreffe de cancer colorectal et de cancer du sein triple négatif L’inactivation du gène [...]

Pages